Search Results for "Hydrocodone Bitartrate 7 5 Mg"

22:40 EDT 28th July 2015 | BioPortfolio

Matching Channels

None

Matching News

Teva Pharma: FDA Accepts For Review NDA For Hydrocodone Bitartrate ER Tablets

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the U.S. FDA has accepted for review the New Drug Application (NDA) for the company's hydrocodone bitartrate extended-r...

Acura to develop hydrocodone/APAP tablets using Limitx technology

US-based Acura Pharmaceuticals has started developing an immediate-release hydrocodone bitartrate with acetaminophen tablet (hydrocodone/APAP) incorporating its new LIMITX abuse deterrent technology.

Acura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen

Acura Pharmaceuticals Inc., announced today that it is initiating development of an immediate-release hydrocodone bitartrate with acetaminophen tablet ("hydrocodone/APAP") incorporating Acura's novel ...

Zogenix intros new formulation for Zohydro ER caps

Ryan ChavisZogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII. read mo...

FDA Accepts Teva's NDA for Abuse-Deterrent Opioid

Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-rel...

Zogenix Closes Sale Of Zohydro ER Business To Pernix

SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...

FDA accepts for review Teva's NDA for pain management tablets

The US Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) for Teva Pharmaceutical's hydrocodone bitartrate extended-release (ER) tablets formulated with its abus...

Survey of hydrocodone patients shows schedule changes negatively impact treatment

A survey of pain patients to assess the effects of rescheduling hydrocodone has shown that it negatively…

Matching PubMed Articles

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.

(1) To quantify hydrocodone (HC) and hydromorphone (HM) metabolite pharmacokinetics with pharmacogenetics in CYP2D6 ultra-rapid (UM), extensive (EM) and poor (PM) metabolizer phenotypes. (2) To develo...

Chemisorptive enantioselectivity of chiral epoxides on tartaric-acid modified Pd(111): three-point bonding.

The chemisorption of two chiral molecules, propylene oxide and glycidol, is studied on tartaric-acid modified Pd(111) surfaces by using temperature-programmed desorption to measure adsorbate coverage....

Rescheduling of Combination Hydrocodone Products: Problems for Long-Term Care Practitioners.

The Drug Enforcement Administration recently announced the final rule to reschedule hydrocodone combinations from schedule III of the Controlled Substances Act to the more restrictive schedule II cate...

Recent developments toward the safer use of opioids in the USA, with a focus on hydrocodone.

Opioids have become a mainstay of treatment for pain in the United States, with over 250 million prescription issued in 2012 alone. The increased prescribing of these medications has also contributed ...

Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.

Abstract Background: Hydrocodone/acetaminophen combination analgesics are frequently prescribed for chronic pain management; however, acetaminophen presents potential hepatotoxicity to patients and th...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement